Sagar Lonial

Active 2001–2026

249
Papers
58,942
Citations
117
h-index
236
i10-index

Citations

Citations per year for Sagar Lonial1948: 2 citations1983: 1 citations1988: 4 citations1990: 3 citations1999: 3 citations2001: 1 citations2002: 1 citations2003: 10 citations2004: 10 citations2005: 16 citations2006: 56 citations2007: 86 citations2008: 153 citations2009: 212 citations2010: 233 citations2011: 319 citations2012: 309 citations2013: 416 citations2014: 496 citations2015: 488 citations2016: 589 citations2017: 616 citations2018: 511 citations2019: 1,979 citations2020: 2,426 citations2021: 2,532 citations2022: 2,124 citations2023: 1,592 citations2024: 2,591 citations2025: 1,071 citations2026: 38 citations1949–1982: no citations, so these years are not shown1984–1987: no citations, so these years are not shown1989: no citations, so this year is not shown1991–1998: no citations, so these years are not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,025 citing papers, 26.6% of this breakdownChina: 1,878 citing papers, 10% of this breakdownGermany: 1,102 citing papers, 5.8% of this breakdownItaly: 1,040 citing papers, 5.5% of this breakdownUnited Kingdom: 1,004 citing papers, 5.3% of this breakdownFrance: 897 citing papers, 4.8% of this breakdownSpain: 816 citing papers, 4.3% of this breakdownCanada: 646 citing papers, 3.4% of this breakdownNetherlands: 561 citing papers, 3% of this breakdownAustralia: 478 citing papers, 2.5% of this breakdownJapan: 389 citing papers, 2.1% of this breakdownGreece: 373 citing papers, 2% of this breakdown
0%26.6%Other 24.7%

Fields

  • Medicine65.8%
  • Biochemistry, Genetics and Molecular Biology27.9%
  • Immunology and Microbiology3.6%
  • Engineering0.4%
  • Computer Science0.4%
  • Chemistry0.4%
  • Other1.5%

Topics

  • Multiple Myeloma Research and Treatments13.9%
  • Protein Degradation and Inhibitors6.5%
  • CAR-T cell therapy research4.7%
  • Peptidase Inhibition and Analysis3.5%
  • Ubiquitin and proteasome pathways3%
  • Cancer, Hypoxia, and Metabolism2.7%
  • Other65.7%

Coauthors

All papers

Open in search
  1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 2,424

  2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau - The Lancet Oncology 2016 cited by 2,995

  3. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 cited by 4,869

  4. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Moreau - Journal of Clinical Oncology 2015 cited by 2,178

  5. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric Lewis, Roxanne C. Jewell, Elisha J. Dettman, Rakesh Popat, Simona Degli Esposti, Joanna Opalinska, Paul G. Richardson, Adam D. Cohen - The Lancet Oncology 2019 cited by 796

  6. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adam D. Cohen, Thomas H. Openshaw, Marcelo C. Pasquini, Sergio Giralt, Jonathan L. Kaufman, Andrew J. Yee, Emma C. Scott, Pallawi Torka, Amy Foley, Mariateresa Fulciniti, Kyle Hebert, Mehmet Samur, Kelly Masone, Michelle E. Maglio, Andrea A. Zeytoonjian, Omar Nadeem, Robert Schlossman, Jacob P. Laubach, Claudia E. Paba‐Prada, Irene M. Ghobrial, Aurore Perrot, Philippe Moreau, Hervé Avet‐Loiseau, Michel Attal, Kenneth C. Anderson, Nikhil C. Munshi - New England Journal of Medicine 2022 cited by 463

  7. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

    Authors: , , , , , , , , , , , , - Blood Cancer Journal 2023 cited by 179

  8. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood 2011 cited by 1,034

  9. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raymond L. Comenzo, Monika Engelhardt, Thomas Illmer, Philip Vlummens, Chantal Doyen, Thierry Façon, Lionel Karlin, Aurore Perrot, Klaus Podar, Michael Kauffman, Sharon Shacham, Lingling Li, Shijie Tang, Carla Picklesimer, Jean‐Richard Saint‐Martin, Marsha Crochiere, Hua Chang, Samir Parekh, Yosef Landesman, Jatin J. Shah, Paul G. Richardson, Sundar Jagannath - New England Journal of Medicine 2019 cited by 673

  10. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Jesús F. San Miguel, Sagar Lonial, Graham Jackson, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth J. Morgan - Leukemia 2018 cited by 453

  11. Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

    Authors: , - CA A Cancer Journal for Clinicians 2023 cited by 97

  12. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 cited by 496

  13. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Jesús F. San Miguel, Sagar Lonial, Graham Jackson, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth J. Morgan - Blood 2018 cited by 495

  14. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jesús F. San Miguel, Kenneth C. Anderson, Edward A. Stadtmauer, Rao Prabhala, Phillip McCarthy, Nikhil C. Munshi - The Lancet Haematology 2022 cited by 191

  15. Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

    Authors: , , , , , , , , , , , , , , , , , , , - Science Signaling 2009 cited by 781

  16. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 1,320

  17. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 929

  18. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 311

  19. Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , S. Vincent Rajkumar, Shaji Kumar, Rafaël Fonseca, Greg Ahmann, P. Leif Bergsagel, A. Keith Stewart, Craig C. Hofmeister, Yvonne A. Efebera, Sundar Jagannath, Ajai Chari, Suzanne Trudel, Donna Reece, Jeffrey Wolf, Thomas Martin, Todd M. Zimmerman, Cara A. Rosenbaum, Andrzej Jakubowiak, Daniel Lebovic, Ravi Vij, Keith Stockerl-Goldstein - Cancer Cell 2014 cited by 1,004

  20. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2015 cited by 762

  21. YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype

    Authors: , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2020 cited by 165

  22. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 cited by 268

  23. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mohamed Elemary, Nizar J. Bahlis, Thierry Façon, Lionel Karlin, Vincent Ribrag, Michel Attal, Hartmut Goldschmidt, Monika Engelhardt, Katja Weisel, Andréas Mackensen, Arnon Nagler, Dina Ben Yehuda, Irit Avivi, Noam Benyamini, Hila Magen‐Nativ, Antonio Palumbo, Michèle Cavo, Kensei Tobinai, Shinsuke Iida, Takaai Chou, Kenshi Suzuki, Hiroshi Kosugi, Masafumi Taniwaki, Kazutaka Sunami, Morio Matsumoto, Kiyoshi Ando, Peter Ganly, Hilary Blacklock, David Simpson, Anupkumar George, Fredrik Schjesvold, Bjørn Tore Gjertsen, Juan José Lahuerta, Joan Bladé, Albert Oriol Rocafiguera, María‐Victoria Mateos, Paula Rodríguez‐Otero, Sarah M. Larson, Djordje Atanackovic, Srinivas Devarakonda, Jacob D. Bitran, Jeffrey A. Zonder, Neil Morganstein, Mohammad Hay, Asher Chanan‐Khan, Gene Saylors, Ebenezer A. Kio, Ira Oliff, Dean Kirkel, Mikhail Shtivelband, Carrie Yuen, Andrew J. Yee, Jatin J. Shah, Myo Htut, Shahzad Raza, Saurabh Chhabra, Patrick J. Stiff, Parameswaran Hari, Bruce Bank, Ehsan Malek, Cristina Gasparetto, Ycaoub Faroun, Daniel W. Sherbenou, William Kreisle, Seema Singhal, Jacalyn Rosenblatt, Saad Z. Usmani, Wes Lee, Hana Safah, Jose Lutzky and 21 more - The Lancet Haematology 2019 cited by 253

  24. Initial genome sequencing and analysis of multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robb Onofrio, Trevor J. Pugh, S. Vincent Rajkumar, Alex H. Ramos, David S. Siegel, Andrey Sivachenko, A. Keith Stewart, Suzanne Trudel, Ravi Vij, Douglas Voet, Wendy Winckler, Todd M. Zimmerman, John D. Carpten, J.M. Trent, William C. Hahn, Levi A. Garraway, Matthew Meyerson, Eric S. Lander, Gad Getz, Todd R. Golub - Nature 2011 cited by 1,455